Green and Black Checkerboard (1 Non-Adhesive Roll ft 300 x 3/16" 1 Tape Flagging Caution & Flagging Tapes


  1. Home
  2. Green and Black Checkerboard (1 Non-Adhesive Roll ft 300 x 3/16" 1 Tape Flagging
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Black and Green Checkerboard Flagging Tape 1 3/16" x 300 ft Roll Non-Adhesive (1
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Brand:

Presco

Model:

Checkerboard

MPN:

FTCBGNBK1

Modified Item: No UPC:

723641150353

ProductName: Black and Green Checkerboard Flagging Tape 1 3/16" Manufacturer: TapePlanet
Size: 1 3/16" x 300' SKU: FTCBGNBK1CS
Country/Region of Manufacture: United States System of Measurement: Standard, Inches/Feet
Type: Flagging Tape Tape Length: 300 ft
Color:

Green/Black

Tape Width: 1 3/16 in
Custom Bundle: No Item Length: 300 ft
Handmade: No Length: 300 ft
published on tue nov 09 2021

Green and Black Checkerboard (1 Non-Adhesive Roll ft 300 x 3/16" 1 Tape Flagging Caution & Flagging Tapes

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Green and Black Checkerboard (1 Non-Adhesive Roll ft 300 x 3/16" 1 Tape Flagging Caution & Flagging Tapes

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS